SURVEY AND SUMMARY

The DNA cleavage reaction of topoisomerase II: wolf in sheep’s clothing

Joseph E. Deweese¹ and Neil Osheroff¹,²,*

¹Department of Biochemistry and ²Department of Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, TN 37232-0146 USA

Received October 7, 2008; Revised October 31, 2008; Accepted November 5, 2008

ABSTRACT

Topoisomerase II is an essential enzyme that is required for virtually every process that requires movement of DNA within the nucleus or the opening of the double helix. This enzyme helps to regulate DNA under- and overwinding and removes knots and tangles from the genetic material. In order to carry out its critical physiological functions, topoisomerase II generates transient double-stranded breaks in DNA. Consequently, while necessary for cell survival, the enzyme also has the capacity to fragment the genome. The DNA cleavage/ligation reaction of topoisomerase II is the target for some of the most successful anticancer drugs currently in clinical use. However, this same reaction also is believed to trigger chromosomal translocations that are associated with specific types of leukemia. This article will familiarize the reader with the DNA cleavage/ligation reaction of topoisomerase II and other aspects of its catalytic cycle. In addition, it will discuss the interaction of the enzyme with anticancer drugs and the mechanisms by which these agents increase levels of topoisomerase II-generated DNA strand breaks. Finally, it will describe dietary and environmental agents that enhance DNA cleavage mediated by the enzyme.

INTRODUCTION

A number of enzymes that catalyze essential physiological processes also have the capacity to damage the genome during the course of their normal activities. For example, while the cell requires DNA polymerases to copy the genetic material, these enzymes insert an incorrect base approximately every 10⁷ nt (1). Consequently, in the absence of mismatch repair pathways, human DNA polymerases would generate several hundred mutations every round of cell division. Furthermore, while DNA glycosylases initiate base-excision repair pathways, these enzymes can convert innocuous lesions to abasic sites with far greater mutagenic potential (2). Finally, while cytochrome P450 enzymes play critical roles in detoxification pathways, they sometimes convert inert xenobiotic chemicals to compounds with mutagenic properties (3).

Of all the enzymes required to sustain cellular growth, topoisomerase II is one of the most dangerous (4–8). As discussed below, this enzyme unwinds, unknits and untangles the genetic material by generating transient double-stranded breaks in DNA (8–12). Although the cell cannot survive without topoisomerase II, the strand breaks that the enzyme generates have the potential to trigger cell death pathways or chromosomal translocations (8,13).

This article focuses on the mechanism by which topoisomerase II cleaves the genetic material, the ability to exploit this reaction for the chemotherapeutic treatment of human cancers and the role of this reaction in triggering specific types of leukemia.

DNA TOPOLOGY

The existence of topoisomerases is necessitated by the structure of the double helix. Each human cell contains ~2 m of DNA that are compacted into a nucleus that is ~10 μm in diameter (14,15). Because the genetic material is anchored to the chromosome scaffold and the two strands of the double helix are plectonemically coiled, accessing the genome is a complex topological challenge (11,12,16–18).

Topological properties of DNA are those that can only be changed when the double helix is broken (12). Two aspects of DNA topology significantly affect nuclear processes. The first deals with topological relationships between the two strands of the double helix. In all living systems, from bacteria to humans, DNA is globally underwound (i.e. negatively supercoiled) by ~6% (12,19–21). This is important because duplex DNA is merely the storage form for the genetic information. In order to replicate or express this information, the two strands of
DNA must be separated. Since global underwinding of the genome imparts increased single-stranded character to the double helix, negative supercoiling greatly facilitates strand separation (12,16–18).

While negative supercoiling promotes many nucleic acid processes, DNA overwinding (i.e. positive supercoiling) inhibits them. The linear movement of tracking enzymes, such as helicases and polymerases, compresses the turns of the double helix into a shorter region (Figure 1) (12,19–21). Consequently, the double helix becomes increasingly overwound ahead of tracking systems. The positive supercoiling that results makes it more difficult to open the two strands of the double helix and ultimately increases overwinding ahead of tracking systems. The linear movement of tracking systems (such as the replication machinery) compresses the turns into a shorter segment of the genetic material and makes it impossible to separate the two strands of the double helix. Moreover, tangled DNA molecules cannot be segregated during mitosis or meiosis (8,10,12,17). Consequently, DNA knots and tangles can be lethal to cells if they are not resolved.

**DNA TOPOISOMERASES**

The topological state of the genetic material is regulated by enzymes known as topoisomerases (8,10,11,22,23). Topoisomerases are required for the survival of all organisms and alter DNA topology by generating transient breaks in the double helix (8,10,11,22,23). There are two major classes of topoisomerases, type I and type II, that are distinguished by the number of DNA strands that they cleave and the mechanism by which they alter the topological properties of the genetic material (8,10,11,22,23).

Eukaryotic type I topoisomerases are monomeric enzymes that require no high-energy cofactor (11,22,24). Type I enzymes are organized into two subclasses: type IA and type IB. These enzymes alter topology by creating transient single-stranded breaks in the DNA, followed by passage of the opposite intact strand through the break (type IA) or by controlled rotation of the helix around the break (type IB) (11,22,24). Type IA topoisomerases need divalent metal ions for DNA scission and attach covalently to the 5′-terminal phosphate of the DNA (11,22,24). In contrast, type IB enzymes do not require divalent metal ions and covalently link to the 3′-terminal phosphate (11,22,24). As a result of their reaction mechanism, type I topoisomerases can modulate DNA underwinding and overwinding, but cannot remove knots or tangles from duplex DNA. A number of excellent review articles on type I topoisomerases have appeared recently (22,24,25). Consequently, these enzymes will not be discussed further in this article.

Eukaryotic type II topoisomerases function as homodimers and require divalent metal ions and ATP for complete catalytic activity (5,8,26–28). These enzymes interconvert different topological forms of DNA by a ‘double-stranded DNA passage reaction’ that can be separated into a number of discrete steps (5,8,26–28). Briefly, type II topoisomerases (i) bind two separate segments of DNA, (ii) create a double-stranded break in one of the segments, (iii) translocate the second DNA segment through the cleaved nucleic acid ‘gate’, (iv) rejoin (i.e. ligate) the cleaved DNA, (v) release the translocated segment through a gate in the protein and (vi) close the protein gate and regain the ability to start a new round of catalysis (5,26–34). Because of their double-stranded DNA passage mechanism, type II topoisomerases can modulate DNA supercoiling and also can remove DNA knots and tangles.

**TOPOISOMERASE II**

Lower eukaryotes and invertebrates encode only a single type II topoisomerase, topoisomerase II (35–38). In contrast, vertebrate species encode two closely related
isomerase IIα and topoisomerase IIβ. These isoforms differ in their protomer molecular masses (170 versus 180 kDa, respectively) and are encoded by separate genes (8,10,22,28,39–46). Topoisomerase IIα and topoisomerase IIβ display a high degree (~70%) of amino acid sequence identity and similar enzymological characteristics. One notable difference between the two isoforms is that topoisomerase IIα relaxes (i.e. removes) positive superhelical twists ~10 times faster than it does negative in vitro, while the β isom form is unable to distinguish the geometry of DNA supercoils during DNA relaxation (47).

Topoisomerase IIα and topoisomerase IIβ have distinct patterns of expression and separate cellular functions. Topoisomerase IIα is essential for the survival of proliferating cells, and protein levels rise dramatically during periods of cell growth (48–51). The enzyme is further regulated over the cell cycle, with protein concentrations peaking in G2/M (50,52,53). Topoisomerase IIα is associated with replication forks and remains tightly bound to chromosomes during mitosis (9,51,54–56). Thus, it is believed to be the isoform that functions in growth-related processes, such as DNA replication and chromosome segregation (10,51).

Topoisomerase IIβ is dispensable at the cellular level but appears to be required for proper neural development (57–59). Expression of topoisomerase IIβ is independent of proliferative status and cell cycle, and the enzyme dissociates from chromosomes during mitosis (54,60,61). Topoisomerase IIβ cannot compensate for the loss of topoisomerase IIα in mammalian cells, suggesting that these two isoforms do not play redundant roles in replicative processes (51,60,62,63). Although the physiological functions of topoisomerase IIβ have yet to be defined, recent evidence indicates involvement in the transcription of hormonally or developmentally regulated genes (63,64).

Much of what we understand regarding the mechanism of action of type II enzymes comes from experiments with topoisomerase II from species that express only a single isoform. Consequently, eukaryotic type II topoisomerases will be referred to collectively as topoisomerase II, unless the properties being discussed are specific to either the α or β isoform.

TOPOISOMERASE II-MEDIATED DNA CLEAVAGE AND LIGATION

The ability of topoisomerase II to cleave and ligate DNA is central to all of its catalytic functions (5,8,11,27). All topoisomerases utilize active site tyrosyl residues to mediate DNA cleavage and ligation. Since type II enzymes cut both strands of the double helix, each protomer subunit contains one of these residues (Tyr805 and Tyr821 in human topoisomerase IIα and topoisomerase IIβ, respectively).

Topoisomerase II initiates DNA cleavage by the nucleophilic attack of the active site tyrosine on the phosphate of the nucleic acid backbone (Figure 2) (11,23,26,27). The resulting transesterification reaction results in the formation of a covalent phosphotyrosyl bond that links the protein to the newly generated 5′-terminus of the DNA chain. It also generates a 3′-hydroxyl moiety on the opposite terminus of the cleaved strand. The scissile bonds on the two strands of the double helix are staggered and are located across the major groove from one another. Thus, topoisomerase II generates cleaved DNA molecules with four-base 5′-single-stranded cohesive ends, each of which is covalently linked to a separate protomer subunit of the enzyme (65–67).

The covalent enzyme–DNA linkage plays two important roles in the topoisomerase II reaction mechanism. First, it conserves the bond energy of the sugar-phosphate DNA backbone. Second, because it does not allow the cleaved DNA chain to dissociate from the enzyme, the protein–DNA linkage maintains the integrity of the genetic material during the cleavage event (11,23,26,27). The covalent topoisomerase II-cleaved DNA reaction intermediate is referred to as the ‘cleavage complex’ and is critical for the pharmacological activities of the enzyme, which are discussed later in this article.

Although topoisomerase II acts globally, it cleaves DNA at preferred sites (68). The consensus sequence for cleavage is weak, and many sites of action do not conform to it (68). Ultimately, the mechanism by which topoisomerase II selects DNA sites is not apparent, and it is nearly impossible to predict de novo whether a given DNA sequence will support scission. Most likely, the specificity of topoisomerase II-mediated cleavage is determined by the local structure, flexibility, or malleability of the DNA that accompanies the sequence, as opposed to a direct recognition of the bases that comprise that sequence (69).

Beyond the nucleophilic attack of the active site tyrosine on the DNA backbone, the details of topoisomerase II-mediated DNA cleavage are not well defined. However, information regarding the roles of specific amino acid residues comes from structural studies on the catalytic core of yeast topoisomerase II generated in the absence of DNA or in a noncovalent complex with its nucleic acid substrate (27,70). For consistency, all amino acid assignments discussed below are for the homologous positions in human topoisomerase IIα.

Figure 2. Double-stranded DNA cleavage mediated by topoisomerase II. Scissile bonds are located four bases apart on opposite strands of the double helix. During cleavage, the active site tyrosine residue of each topoisomerase II protomer subunit becomes covalently linked to the newly generated 5′-terminal phosphate moiety on each strand. This covalent linkage preserves the energy of the sugar-phosphate DNA backbone. The newly generated 3′-hydroxyl group interacts with topoisomerase II in a noncovalent fashion. Ligation represents the reverse of this process and leaves the DNA product chemically unchanged from the initial substrate.
While not all of the amino acids involved in catalysis have been elucidated, it is believed that the enzyme utilizes a general acid-base mechanism for DNA cleavage (Figure 3). Cleavage is initiated when a general base deprotonates the active site tyrosine hydroxyl, allowing the oxyanion to attack the scissile phosphate. The base has not been identified but is believed to be a conserved histidine residue.

The DNA cleavage reaction requires a divalent metal ion (5,30,34,71,72). Mg$^{2+}$ appears to fulfill this function in vivo (5). Recent evidence indicates that human topoisomerase II$\alpha$ utilizes a ‘two-metal-ion’ mechanism, in which one of the metal ions interacts with the bridging 5’-oxygen of the scissile bond (34). This interaction greatly accelerates rates of enzyme-mediated DNA cleavage and most likely is needed to stabilize the leaving 3’-oxygen. The role of the second metal ion is not known. However, it is believed to make critical contacts with the active site tyrosine and may stabilize the DNA transition state and/or help deprotonate the active site tyrosine (34,73). It has been postulated that the divalent metal ions are coordinated by Glu461, Asp541, Asp543 and Asp545 in human topoisomerase II$\alpha$ and corresponding residues in the β isoform (Figure 3) (34,70,74,75). A two-metal-ion mechanism for DNA cleavage mediated by the bacterial type II topoisomerase, DNA gyrase, also has been proposed (73).

Topoisomerase II–DNA cleavage complexes normally are short-lived and readily reversible (5,8,76), and the DNA cleavage/ligation equilibrium of the enzyme greatly favors ligation (5,8,11,23,26,27,77,78). Under equilibrium conditions, ~0.5–1% of topoisomerase II in a DNA scission reaction mixture exists as a cleavage complex (65–67,78,79). Furthermore, when Mg$^{2+}$ is utilized as the divalent metal ion, ~1/2–3/4 of the complexes contain double-stranded breaks with the remainder containing single-stranded DNA breaks. The fact that a significant proportion of cleavage complexes contain single-stranded breaks was initially taken as an indication for poor coordination between the two protomer subunits of topoisomerase II (80). However, with hindsight, if the protomers cut the two strands of the double helix in a completely noncoordinated fashion, virtually no double-stranded DNA breaks would be generated (1% × 1% ≈ 0.01% cleavage complexes). These findings suggest that there must be a relatively high degree of coordination between the two protomer active sites of the enzyme, even if they do not act in complete concert with one another (78). To this point, once topoisomerase II cleaves the first strand, it is estimated that the enzyme cuts the second strand ~20-fold faster (77,78).

Following strand passage, DNA ligation is initiated when a general acid extracts the hydrogen from the 3’-terminal hydroxyl group. The acid may be a water molecule or an unidentified amino acid in the active site of topoisomerase II. The conversion of the terminal hydroxyl moiety to an oxyanion induces a nucleophilic attack on the phosphotyrosyl bond (11,23,26,27). This action represents the reverse of the cleavage event and regenerates an intact DNA chain as well as the active site of topoisomerase II.

It should be noted that the chemical structure of the ligated DNA is identical to that of the original substrate. Only the topological properties of the double helix are altered by the actions of topoisomerase II.

**Figure 3.** Mechanism of DNA cleavage and ligation mediated by topoisomerase II. The type II enzyme utilizes a two-metal ion mechanism similar to that utilized by primases and polymerases (34,70,71,74–77,155,156). Amino acids that are postulated to interact with the metal ions in the active site of topoisomerase II$\alpha$ and topoisomerase II$\beta$ are indicated. One of the metal ions (shown at left) makes a critical interaction with the 3’-bridging atom of the scissile phosphate (bond shown in red), which most likely is needed to stabilize the leaving 3’-oxygen (shown in red). A second metal ion (shown at right) is required for DNA scission and may stabilize the DNA transition state and/or help deprotonate the active site tyrosine (Y805 in topoisomerase II$\alpha$ and Y821 in topoisomerase II$\beta$). Cleavage is initiated when a general base deprotonates the active site tyrosine hydroxyl, allowing the oxyanion to attack the scissile phosphate. The base has not been identified but is believed to be a conserved histidine residue. Ligation is initiated when a general acid extracts the hydrogen from the 3’-terminal hydroxyl group. The acid may be a water molecule or an unidentified amino acid in the active site of topoisomerase II. Figure adapted from Noble and Maxwell (73).

**TOPOISOMERASE II AS A CELLULAR TOXIN**

Proliferating cells cannot exist without type II topoisomerases (5,8,10). However, since these enzymes generate obligatory double-stranded DNA breaks as part of their reaction mechanism, they are intrinsically dangerous proteins. Thus, topoisomerase II assumes a Dr. Jekyll/Mr. Hyde character; while essential to cell viability, the enzyme also has the capacity to fragment the genome (Figure 4). Because of this dual persona, levels of cleavage complexes are maintained in a critical balance (5,8). When levels drop below threshold concentrations, daughter chromosomes remain entangled following replication. As a result, chromosomes cannot segregate properly during mitosis and cells die as a result of catastrophic mitotic failure (Figure 4).
leukemia that involve the poisons has been associated with the formation of specific types of DNA breaks in surviving populations. In some cases, exposure to topoisomerase II poisons can overwhelm the cell, triggering apoptosis. This is the basis for the translocations and other DNA aberrations. If the strand breaks interfere with recombination/repair pathways and generate chromosome breaks, the enzyme cannot perform its critical functions. If the level of topoisomerase II–DNA cleavage complexes is required for transcription, the enzyme is no longer tethered by proteinaceous bridges (8). These chemicals form noncovalent interactions with topoisomerase II at the protein–DNA interface in the vicinity of the active site tyrosine (8,46,84–87). Because these compounds also interact with DNA within the ternary enzyme–DNA–poison complex, they generally alter the DNA cleavage site specificity of the enzyme (88). Finally, their actions against topoisomerase II are not affected by reducing agents, such as dithiothreitol, and these compounds induce similar levels of enzyme-mediated DNA cleavage whether they are added to the binary topoisomerase II–DNA complex or are incubated with the enzyme prior to the addition of nucleic acid substrates (8,82,83,89).

Unlike the traditional poisons, compounds that use the second mechanism require redox activity to facilitate their actions against topoisomerase II. The redox-dependent poisons covalently adduct to the enzyme at amino acid residues outside of the active site (8,76,89–96) and generally enhance DNA cleavage at sites that are intrinsically cut by the enzyme (89,94). Moreover, because these compounds require redox chemistry for activation, their ability to poison topoisomerase II is abrogated by reducing agents (89,91,94,97–99). Finally, compounds within this group enhance DNA cleavage when added to the protein–DNA complex, but display the distinguishing feature of inhibiting topoisomerase II activity when incubated with the enzyme prior to the addition of DNA (89,91,94,97–99).

TOPOISOMERASE II AS A TARGET FOR ANTICANCER DRUGS

Topoisomerase II poisons represent some of the most important and widely prescribed anticancer drugs currently in clinical use (Figure 5). These drugs encompass a diverse group of natural and synthetic compounds that are commonly used to treat a variety of human

Figure 4. Topoisomerase II is an essential but genotoxic enzyme. The formation of topoisomerase II–DNA cleavage complexes is required for the enzyme to perform its critical cellular functions. If the level of topoisomerase II–DNA cleavage complexes falls too low (left arrow), cells are not able to untangle daughter chromosomes and ultimately die of mitotic failure. If the level of cleavage complexes becomes too high (right arrow) the actions of DNA tracking systems can convert these transient complexes to permanent double-stranded breaks. The resulting DNA breaks, as well as the inhibition of essential DNA processes, initiate recombination/repair pathways and generate chromosome translocations and other DNA aberrations. If the strand breaks overwhelm the cell, they can trigger apoptosis. This is the basis for the formation of specific types of leukemia that involve the poisons and convert it to a cellular toxin that initiates the mutagenic and lethal consequences described above (5,8,76). Because of their actions, these compounds are referred to as ‘topoisomerase II poisons’ to distinguish them from inhibitors that do not affect enzyme-mediated DNA cleavage/ligation (5,8,76). Although some topoisomerase II poisons also inhibit overall activity, the ‘gain of function’ induced by these compounds in the cell (i.e. increased levels of cleavage complexes) is a dominant phenotype (8,76).

Topoisomerase II poisons increase the concentration of cleavage complexes by two nonmutually exclusive pathways. Some compounds, such as the anticancer drug etoposide (see below), act by inhibiting the ability of the enzyme to ligate cleaved DNA molecules (5,8,76,78). Other poisons, such as abasic sites and other forms of DNA damage (see below) work primarily by enhancing the forward rate of scission (8,76,78). Because of the manner in which they act, abasic sites poison topoisomerase II without inhibiting overall catalytic activity.

Beyond their effects on DNA scission versus ligation, topoisomerase II poisons (with the exception of DNA lesions) act by two distinct mechanisms. Compounds in the first group are referred to as traditional, noncovalent, interfacial or redox-independent topoisomerase II poisons (8,46,76,82). These chemicals form noncovalent interactions with topoisomerase II at the protein–DNA interface in the vicinity of the active site tyrosine (8,46,84–87). Because of their actions against topoisomerase II, they are commonly used to treat a variety of human
malignancies (5,8,76,82,100,101). At the present time, six topoisomerase II-targeted anticancer agents are approved for use in the United States, and additional drugs are prescribed elsewhere in the world (101). These agents all act as traditional topoisomerase II poisons and function primarily by inhibiting enzyme-mediated DNA ligation.

One of the first topoisomerase II-targeted agents to be discovered was etoposide, which is derived from podophyllotoxin (100,102). This natural product is found in Podophyllum peltatum, more commonly known as the mayapple or mandrake plant (100,102). Podophyllotoxin has been used as a folk remedy for over a 1000 years (100,102). The clinical use of this compound as an antineoplastic agent was prevented by high toxicity, but two synthetic analogs, etoposide and teniposide, displayed increased antineoplastic activity and decreased toxicity (100,102). Etoposide was approved for clinical use against cancer in the mid-1980s and for several years was the most widely prescribed anticancer drug in the world (100,102).

Etoposide and other drugs such as doxorubicin (and its derivatives) are front-line therapy for a variety of systemic cancers and solid tumors, including leukemias, lymphomas, sarcomas and breast, lung and germline cancers (100–102). Mitoxantrone is used to treat breast cancer, and both it and amsacrine are used to treat relapsed acute myeloid leukemia (103,104). Every form of cancer that is considered to be curable by chemotherapy utilizes treatment regimens that include topoisomerase II-targeted drugs (100–102,105). In addition to the use of mitoxantrone in anticancer regimens, it is used as a treatment for autoimmune diseases, such as multiple sclerosis (106).

Although topoisomerase II is the cytotoxic target of the drugs shown in Figure 5, the relative contributions of topoisomerase IIα and topoisomerase IIβ to the chemotherapeutic effects of these agents has yet to be resolved. Some drugs appear to favor one isoform or the other; however, no truly ‘isoform-specific’ agents have been identified. The issue of isoform specificity has potential clinical ramifications. For example, since topoisomerase IIα is not expressed appreciably in quiescent cells, the actions of topoisomerase II-targeted agents against the β isoform in differentiated tissues, such as cardiac cells, most likely are responsible for much of the off-target toxicity of these drugs (107–109). Alternatively, since topoisomerase IIα and topoisomerase IIβ are involved in different cellular processes, it may be that cleavage complexes formed with one or the other isoform are more likely to be converted to permanent DNA strand breaks.

**Figure 5.** Topoisomerase II anticancer drugs. Structures of selected topoisomerase II-targeted anticancer drugs are shown.

**Figure 6.** Dietary, environmental and DNA-based topoisomerase II poisons. Abbreviations used are epigallocatechin gallate (EGCG), N-acetyl-p-benzoquinone imine (NAPQI) and 2-(4-chloro-phenyl)-[1,4]benzoquinone (4Cl-2,5pQ).

---

**DIETARY TOPOISOMERASE II POISONS**

Many foods consumed in the human diet contain naturally occurring topoisomerase II poisons (Figure 6).
The most prominent natural products with activity against the mammalian type II enzymes are the bioflavonoids (i.e. phytoestrogens) (110–113). Bioflavonoids represent a broad group of polyphenolic compounds (including flavones, flavonols, isoflavones and catechins) that are components of many fruits, vegetables and plant leaves (114–117). These compounds affect human cells through a variety of pathways; they are strong antioxidants and efficient inhibitors of growth factor receptor tyrosine kinases (114–117). In addition, many bioflavonoids, especially genistein, are potent topoisomerase II poisons (90,110–113,118–122).

Genistein, which is prominent in soy, is believed to be a chemopreventative agent in adults that contributes to the low incidence of breast and colorectal cancers in the Pacific Rim (Figure 6) (116,117). However, as discussed below, there also is evidence associating genistein consumption during pregnancy with the development of infant leukemias (111,123–126). In addition, (–)-epigallocatechin gallate (EGCG), the most abundant and biologically active polyphenol in green tea, is a topoisomerase II poison (Figure 6) (90,116,121). Many of the therapeutic benefits of green tea have been attributed to this compound.

The ring structure of genistein is remarkably similar to that of quinolones (122). These latter compounds, which target the prokaryotic type II topoisomerases DNA gyrase and topoisomerase IV, represent the most active and broad-spectrum antibacterials currently in clinical use (127–129). Like the quinolones and the anticancer drugs discussed above, genistein increases levels of topoisomerase II–DNA cleavage complexes as a traditional topoisomerase II poison (122). In contrast, since many bioflavonoids undergo redox chemistry, several members of the class act as redox-dependent topoisomerase II points. EGCG and some related catechins poison topoisomerase II by this latter mechanism (90,121).

ENVIRONMENTAL TOPOISOMERASE II POISONS

The toxic metabolites of some drugs and industrial chemicals are topoisomerase II poisons (Figure 6) (92,93,95,130,131). In all cases described to date, these chemicals include quinones (aromatic rings that feature ketone groups) as part of their structures (132–135). Quinones commonly are produced in the body as a result of detoxification or metabolism pathways (132–135). These compounds are highly reactive and often damage cells by generating oxidative radicals and by covalently modifying proteins and (to a lesser extent) nucleic acids (132–135).

Although acetaminophen is the most widely utilized analgesic in the world, the second most prevalent cause of toxic drug admissions to emergency departments in the United States is overdose (both accidental and intentional) of this drug (136). The toxic metabolite of acetaminophen, N-acetyl p-benzoquinone imine (NAPQI), is a potent topoisomerase II poison that produces liver failure (96). Benzene is an industrial solvent that is associated with the development of human leukemias (130,132–135). One of the most prevalent metabolites of benzene, 1,4-benzoquinone, is a highly reactive topoisomerase II poison (92,93,95,130,131). Finally, polychlorinated biphenyls (PCBs), which have multiple industrial uses, have been linked to a variety of human health issues (94). The quinone metabolites of these compounds display activity against human type II topoisomerases. Consistent with their highly active redox chemistry, all quinone-based topoisomerase II poisons act in a redox-dependent manner that involves covalent attachment to the enzyme (91–93,97).

DNA DAMAGE AS TOPOISOMERASE II POISONS

Several forms of nucleic acid damage enhance topoisomerase II-mediated DNA cleavage (Figure 6) (69,78,137–144). The type II enzymes are particularly sensitive to abasic sites, alkylated bases that contain exocyclic rings, and other lesions that distort the double helix.

DNA damage increases cleavage at naturally occurring sites of topoisomerase II action (69,78,137–144). In order to enhance cleavage, lesions must be located within the four-base stagger that separates the two scissile bonds (69,78,137–144). Unlike the traditional and redox-dependent topoisomerase II poisons discussed above, DNA damage has no obvious effect on rates of topoisomerase II-mediated ligation and appears to act primarily by enhancing the forward rate of scission (69,78,137–144).

The physiological benefits of DNA lesions as topoisomerase II poisons, if any, are unclear. However, human topoisomerase IIα and topoisomerase IIβ both appear to play roles in fragmenting genomic DNA and releasing chromosomal loops during apoptosis (145,146). It has been suggested that the apoptotic activities of topoisomerase II are enhanced (or perhaps triggered) by DNA lesions that are generated following the release of oxidative radicals from permeable mitochondria in apoptotic cells (145,146).

TOPOISOMERASE II AND LEUKEMIA

Despite the importance of topoisomerase II in cancer chemotherapy, evidence suggests that DNA cleavage mediated by the enzyme can trigger chromosomal translocations that lead to specific types of leukemia (Figure 4) (5–8,76,147,148). To this point, 2–3% of patients who receive regimens that include etoposide or other topoisomerase II-targeted drugs eventually develop acute myeloid leukemias (AMLs). Most of these leukemias are accompanied by translocations with breakpoints in the MLL (mixed lineage leukemia) gene at chromosomal band 11q23 (6,7,76). The MLL protein is a histone methyltransferase that regulates the Hox genes, which control proliferation in hematopoietic cells (6,7,76). Several breakpoints in MLL have been identified and are located in close proximity to topoisomerase II–DNA cleavage sites (6,7,76).

Recently, a link between topoisomerase II-targeted drugs and the development of acute promyeloctytic leukemias (APLs) has been observed. Patients with these leukemias display translocations between the PML (promyeloctytic leukemia) gene on chromosome 15 and the
RARA (retinoic acid receptor \( \alpha \)) gene on chromosome 17 (149,150).

In addition to treatment-related leukemias, \(~80\%\) of infants with AML or acute lymphoblastic leukemia (ALL) display translocations that involve the MLL gene (6,7,111,123–125,147,148,151). The chromosomal translocations associated with these cancers have been observed in utero, indicating that infant leukemias are initiated during pregnancy. Epidemiological studies indicate that the risk of developing these infant leukemias is increased \(>3\)-fold by the maternal consumption of foods that are high in naturally occurring topoisomerase II poisons such as genistein or other bioflavonoids (111,123–126).

The ability of topoisomerase II poisons to ‘cause’ rather than ‘cure’ cancer may be related to cellular levels of topoisomerase II-mediated DNA cleavage complexes. If the concentration of enzyme-associated DNA breaks is sufficient, DNA recombination/repair pathways can be overwhelmed and cells will die (5,8,76). However, if the levels of breaks are not adequate to induce death, pathways that promote cell survival can lead to the formation of stable chromosomal translocations that ultimately lead to cancerous growth (Figure 4) (5,8,76).

Finally, the specific contributions of topoisomerase II\(\alpha\) and topoisomerase II\(\beta\) to cancer therapy versus leukemogenesis are unclear. However, evidence suggests that (with at least some drugs) topoisomerase II\(\alpha\) plays a more important role in cytotoxicity (107,152), while topoisomerase II\(\beta\) may play a greater role in triggering drug-induced cancers (107). Although no isoform-specific topoisomerase II-targeted drugs are available at the present time, it may be possible to preferentially target topoisomerase II\(\alpha\) by scheduling. In this regard, topoisomerase II\(\alpha\)–DNA cleavage complexes induced by etoposide persist approximately three to four times longer than those formed with topoisomerase II\(\beta\) (153,154). Therefore, it has been suggested that the use of pulsed chemotherapeutic regimens, in which patients receive cycles of drug treatment followed by recovery, may maintain higher levels of topoisomerase II\(\alpha\) as compared to topoisomerase II\(\beta\) cleavage complexes over the course of therapy (154).

ACKNOWLEDGEMENTS

We are grateful to Amanda C. Gentry and Adam C. Ketron for critical reading of the manuscript.

FUNDING

The National Institutes of Health (GM33944 and GM53960); National Institutes of Health (T32 CA09592 to J.E.D.). Funding for open access charge: National Institutes of Health (GM33944 and GM53960).

Conflict of interest statement. None declared.

REFERENCES

1. Loeb,L.A. and Monnat,R.J. Jr. (2008) DNA polymerases and human disease. Nat. Rev. Genet., 9, 594–604.

2. Hedge,M.L., Hazra,T.K. and Mitra,S. (2008) Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res., 18, 27–47.

3. Guengerich,F.P. (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 8, E101–E111.

4. Baguley,B.C. and Ferguson,L.R. (1998) Mutagenic properties of topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 213–222.

5. Fortune,J.M. and Osheroff,N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol., 64, 221–253.

6. Felix,C.A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol., 36, 525–535.

7. Felix,C.A., Kolaris,C.P. and Osheroff,N. (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst.), 5, 1093–1108.

8. McClendon,A.K. and Osheroff,N. (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res., 623, 83–97.

9. Nitis,J.L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta, 1400, 63–81.

10. Wang,J.C. (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol., 3, 430–440.

11. Wang,J.C. (1996) DNA topoisomerases. Annu. Rev. Biochem., 65, 635–692.

12. Bates,A.D. and Maxwell,A. (2005) DNA Topology. Oxford University Press New York.

13. Kaulmann,S.H. (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta, 1400, 195–211.

14. Kornberg,A. and Baker,T.A. (1992) DNA replication. 2nd edn. W. H. Freeman, New York.

15. Voet,D., Voet,J.G. and Pratt,C.W. (2006) Fundamentals of Biochemistry. 2nd edn. John Wiley & Sons, Hoboken, N.J.

16. Espeli,O. and Marians,K.J. (2004) Untangling intracellular DNA topology. Mol. Microbiol., 52, 925–931.

17. Falaschi,A., Abdurashidova,G., Sandoval,O., Radulescu,S., Biamonti,G. and Riva,S. (2007) Molecular and structural transactions at human DNA replication origins. Cell Cycle, 6, 1705–1712.

18. Travers,A. and Muskeshihvili,G. (2007) A common topology for bacterial and eukaryotic transcription initiation? EMBO Rep., 8, 147–151.

19. Bauer,W.R., Crick,F.H. and White,J.H. (1980) Supercoiled DNA. Sci. Am., 243, 100–113.

20. Vologodskii,A.V. and Cozzarelli,N.R. (1994) Conformational and thermodynamic properties of supercoiled DNA. Annu. Rev. Biophys. Biomol. Struct., 23, 609–643.

21. White,J.H. and Cozzarelli,N.R. (1984) A simple topological method for describing stereoisomers of DNA catenanes and knots. Proc. Natl Acad. Sci. USA, 81, 3322–3326.

22. Champoux,J.J. (2001) DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem., 70, 369–413.

23. Schoeffer,A.J. and Berger,J.M. (2005) Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem. Soc. Trans., 33, 1465–1470.

24. Leppard,J.B. and Champoux,J.J. (2005) Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma, 114, 75–85.

25. Pommier,Y. (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 6, 789–802.

26. Wang,J.C. (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Quart. Rev. Biophys., 31, 107–144.

27. Berger,J.M., Gamblin,S.J., Harrison,S.C. and Wang,J.C. (1996) Structure and mechanism of DNA topoisomerase II. Nature, 379, 225–232.

28. Velez-Cruz,R. and Osheroff,N. (2004) Encyclopedia of Biological Chemistry. Elsevier Inc., San Diego, CA, pp. 806–811.

29. Osheroff,N. (1986) Eukaryotic topoisomerase II. Characterization of enzyme turnover. J. Biol. Chem., 261, 9944–9950.

30. Osheroff,N. (1987) Role of the divalent cation in topoisomerase II mediated reactions. Biochemistry, 26, 6402–6406.

31. Lindsley,J.E. and Wang,J.C. (1993) On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J. Biol. Chem., 268, 8096–8104.
32. Roa,J., and Wang J.C. (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell, 71, 833–840.

33. Wilsternann,A.M. and Osheroff,N. (2001) Positioning the 3′-DNA terminus for topoisomerase II-mediated religation. J. Biol. Chem., 276, 17727–17731.

34. Deweeze,J.E., Burgin,A.B. and Osheroff,N. (2008) Human topoisomerase II uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res., 36, 4883–4893.

35. Goto,T. and Wang,J.C. (1982) Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings. J. Biol. Chem., 257, 5866–5872.

36. Bossard,J., Laipis,P. and Wang,J.C. (1984) The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae. J. Biol. Chem., 259, 10422–10429.

37. Drake,F.H., Hofmann,G.A., Bartus,H.F., Mattern,M.R., Sullivan,D.M., Ross,W.E., Mattern,M.R., Johnson,R.K. and Crooke,S.T. (1987) Purification of type II DNA topoisomerase from amsa-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem., 262, 16739–16747.

38. Tsai-Pillifielder,M., Liu,L.-F., Liu,A.A., Deweese,J.E. and Osheroff,N. (2008) Human topoisomerase II: its role in cell cycle regulation. Cell Growth Differ., 19, 1201–1205.

39. Perkins,S.L. and Osheroff,N. (1989) Double-stranded DNA cleavage/religation reaction of mammalian DNA topoisomerase II. Biochim. Biophys. Acta, 1073–1080.

40. Perkins,S.L. (1997) Differential immunohistochemical staining for DNA topoisomerases I and II in human tissues and for DNA topoisomerase II in non-Hodgkin’s lymphomas. Mod. Pathol., 10, 168–175.

41. Rubins,A. and Osheroff,N. (1998) Topoisomerase II: structure, regulation and inhibition. J. Biol. Chem., 273, 33660–33666.

42. Beck,M.M., Hittelmann,W.N. and Earnshaw,W.C. (1988) Differential expression of DNA topoisomerases I and II during the erythroid cell cycle. Proc. Natl Acad. Sci. USA, 85, 1086–1090.

43. Kimura,K., Saio,M., Ui,M. and Enomoto,T. (1994) Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J. Biol. Chem., 269, 1176–1176.

44. Linka,R.M., Porter,A.C., Volkov,A., Mielke,C., Boege,F. and Christensen,M.O. (2007) C-terminal regions of topoisomerase IIα and IIβ determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res., 35, 3810–3822.

45. Bauman,M.E., Hui,F.K., Hais,J., Yee,A.A., Harker,W.G. and Perkins,S.L. (1997) Differential immunohistochemical staining for DNA topoisomerase IIα and IIβ in human tissues and for DNA topoisomerase IIβ in non-Hodgkin’s lymphomas. Mod. Pathol., 10, 168–175.

46. Christensen,M.O., Larson,K.S., Barthelmes,H.U., Hock,R., Andersen,C.L., Kjeldsen,E., Knudsen,B.R., Westergaard,O., Boege,F. and Mielke,C. (2002) Dynamics of human DNA topoisomerases Iα and IIβ in living cells. J. Cell Biol., 157, 31–44.

47. Chen,M. and Beck,W.T. (1995) DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol. Res., 7, 103–111.

48. Dereuddre,S., Delaporte,C. and Auckly-Sablon,A. (1997) Role of topoisomerase IIα in the resistance of 9-OH-ellipticine-resistant Chinese hamster V79 fibroblasts to topoisomerase II inhibitors. Cancer Res., 57, 4301–4308.

49. Yang,X., Li,W., Prescott,E.D., Burden,S.J. and Wang,J.C. (2000) DNA topoisomerase IIα and neural development. Science, 287, 131–144.

50. Austin,C.A. and Marsh,K.L. (1998) Eukaryotic DNA topoisomerase IIβ. BioEssays, 20, 215–226.

51. Isaacs,R.J., Davies,S.L., Sandri,M.L., Redwood,C., Wells,N.J. and Hickson,I.D. (1998) Physiological regulation of eukaryotic topoisomerase II. Biochim. Biophys. Acta, 1400, 121–137.

52. Sakaguchi,A. and Kikuchi,A. (2004) Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J. Cell Sci., 117, 1047–1054.

53. Bu,B.G., Lunak,V.V., Perissi,V., Garcia-Bassols,J., Rose,D.W., Glass,C.K. and Rosenfeld,M.G. (2006) A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science, 312, 1798–1802.

54. Haine,J.F., Rouleau,M. and Poirier,G.G. (2006) Transcription. Gene expression needs a break to unwind before carrying on. Science, 312, 1752–1753.

55. Zechiedrich,E.L., Christiansen,K., Andersen,A.H., Westergaard,O. and Osheroff,N. (1989) Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry, 28, 6229–6236.

56. Liu,L.-F., Rowe,T.C., Yang,L., Deweese,J.E. and Chen,G.L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem., 258, 15365–15370.

57. Sandner,N. and Hsieh,T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem., 258, 8421–8428.

58. Capranico,G. and Binaschi,M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta, 1400, 185–194.

59. Velez-Cruz,R., Riggins,J.N., Daniels,J.S., Cai,H., Guengerich,F.P., Marnett,L.J. and Osheroff,N. (2005) Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells. Biochemistry, 44, 3972–3981.

60. Dong,K.C. and Berger,J.M. (2007) Structural basis for gate-DNA recruitment and bending by type IIA topoisomerases. Nature, 450, 1201–1205.

61. Aravind,L., Leipe,D.D. and Koonin,E.V. (1998) Toprims—a conserved catalytic domain in type Iα and II topoisomerases, DNA-gtime primases, OLD family nucleases and RecR proteins. Nucleic Acids Res., 26, 4205–4213.

62. Berger,J.M., Fass,D., Wang,J.C. and Harrison,S.C. (1998) Structural similarities between topoisomerases that cleave one or both DNA strands. Proc. Natl Acad. Sci. USA, 95, 7876–7881.
92. Bender, R.P. and Osheroff, N. (2007) Mutation of cysteine residue
90. Bandele, O.J. and Osheroff, N. (2008) (-)-Epigallocatechin gallate,
89. Lindsey, R.H. Jr, Lightower, R., Turnbull, R.M. and Osheroff, N. (2006) Mutation P732L in human DNA topoisomerase IIb abolishes DNA cleavage in the presence of calcium and confers drug resistance. Mol. Pharmacol., 69, 130–139.
87. Mueller-Planitz, F. and Herschlag, D. (2008) Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: A unifying kinetic and structural mechanism. J. Biol. Chem., 283, 17463–17476.
86. Dewees, J.E., Burgin, A.B. and Osheroff, N. (2008) Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase II. Biochemistry, 47, 4129–4140.
85. Kingma, P.S., Burden, D.A. and Osheroff, N. (1999) Binding of a human topoisomerase II poison human topoisomerase II: altering enzyme function by blocking the N-terminal protein gate. Biochemistry, 45, 10140–10152.
84. Lindsey, R.H. Jr, Bender, R.P. and Osheroff, N. (2005) Effects of benzene metabolites on DNA cleavage mediated by human topoisomerase II: 1,4-hydroquinone is a topoisomerase II poison. Chem. Res. Toxicol., 18, 761–770.
83. Lindsey, R.H. Jr, Castner, R.P., Bender, R.P., Burden, D.A. and Osheroff, N. (2004) N-acetyl-p-benzoquinone imine, the toxic metabolite of acetalaminophen, is a topoisomerase II poison. Biochemistry, 43, 3731–3739.
82. Frydman, B., Marton, L.J., Sun, S.S., Neder, K., Wita, D.T., Liu, A.A., Wang, H.M., Mao, Y., Wu, H.Y., Sanders, M.M. et al. (1997) Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related napthoquinones. Cancer Res., 57, 620–627.
81. Frantz, C.E., Chen, H. and Eastmond, D.A. (1996) Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. Environ. Health Perspect., 104 (Suppl. 6), 1319–1323.
80. Baker, R.K., Kurz, E.U., Pyatt, D.W., Irons, R.D. and Kroll, D.J. (2001) Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase II. Blood, 98, 830–833.
79. Baldwin, E.L. and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents, 5, 363–372.
78. Martinic, D. and Hande, K.R. (2005) Topoisomerase II inhibitors. Cancer Chemother. Biol. Response Modif., 22, 101–121.
77. Hande, K.R. (1999) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer, 34, 1514–1521.
76. Kell, J. (2006) Treatment of relapsed acute myeloid leukaemia. Rev. Recent Clin. Trials, 1, 103–111.
75. Coley, H.M. (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev., 34, 378–390.
74. Burden, D.A. and Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400, 139–154.
73. Gold, R. (2008) Combination therapies in multiple sclerosis. J. Neurol., 255(Suppl. 1), 51–60.
72. Azarova, A.M., Lyu, Y.L., Lin, C.P., Tsai, Y.C., Lau, J.Y., Wang, J.C. and Liu, L.F. (2007) Roles of DNA topoisomerase II isoforms in chemotherapy and secondary malignancies. Proc. Natl Acad. Sci. USA, 104, 11014–11019.
71. Lu, Y.L., Lin, C.P., Azarova, A.M., Cai, L., Wang, J.C. and Liu, L.F. (2006) Role of topoisomerase II in the expression of developmentally regulated genes. Mol. Cell. Biol., 26, 7929–7941.
70. Schested, M., Jensen, P.B., Sorensen, B.S., Holm, B., Friche, E. and Demant, E.J. (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46, 389–393.
69. Constantinou, A., Mehta, R., Runyan, C., Rao, K., Vaughan, A. and Moon, R. (1995) Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J. Nat. Prod., 58, 217–225.
68. Strick, R., Strissel, P.L., Borgers, S., Smith, S.L. and Rowley, J.D. (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc. Natl Acad. Sci. USA, 97, 4790–4795.
67. Martin-Cordero, C., Lopez-Lazaro, M., Pinero, J., Ortiz, T., Cortes, F. and Ayuso, M.J. (2000) Glucosylated isoflavones as DNA topoisomerase II poisons. J. Enzyme Inhib., 15, 455–460.
66. Galati, G. and O'Brien, P.J. (2004) Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic. Biol. Med., 37, 287–303.
65. Adamecz, H. and Watanabe, S. (1995) Plasma concentrations of phyto-oestrogens in Japanese men. Lancet, 342, 1209–1210.
64. lamartiniere, C.A. (2000) Protection against breast cancer with genistein: a component of soy. Am. J. Clin. Nutr., 71, 1705S–1707S; discussion 1708S–1709S.
63. Siddiqui, A.A., Adhami, V.M., Saleem, M. and Mukhtar, H. (2006) Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res., 50, 130–143.
117. Surkar,F.H., Adsule,S., Padhye,S., Kulkarni,S. and Li,Y. (2006) The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. *Mini Rev. Med. Chem.*, 6, 401–407.
118. Markovits,J., Linasser,C., Fosse,P., Couprie,J., Pierre,J., Jacquemin-Sablon,A., Sauzier,J.M., Le Peouc,J.B. and Larsen,A.K. (1989) Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. *Cancer Res.*, 49, 5111–5117.
119. Austin,C.A., Patel,S., Ono,K., Nakane,H. and Fisher,L.M. (1992) Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. *Biochem. J.*, 282, 883–889.
120. Markovits,J., Junqua,S., Goldwasser,F., Venuat,A.M., Luccioni,C., Beaumatin,J., Sauzier,J.M., Bernheim,A. and Jacquemin-Sablon,A. (1995) Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform. *Biochem. Pharmacol.*, 50, 177–186.
121. Bandele,O.J., Clawson,S.J. and Osheroff,N. (2008) Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. *Chem. Res. Toxicol.*, 21, 123–120.
122. Bandele,O.J. and Osheroff,N. (2007) Bioflavonoids as poisons of human topoisomerase IIa and IIb. *Biochem.*, 46, 6097–6108.
123. Ross,J.A., Potter,J.D. and Robison,L.L. (1994) Infant leukemia, topoisomerase II inhibitors, and the MLL gene. *J. Natl. Cancer Inst.*, 86, 1678–1689.
124. Ross,J.A., Potter,J.D., Reaman,G.H., Pendergrass,T.W. and Anderson,V.E. and Osheroff,N. (2001) Type II topoisomerases to infant leukemia? *Cancer Causes Control*, 12, 581–590.
125. Ross,J.A. (2000) Dietary flavonoids and the MLL gene: a pathway to infant leukemia? *Proc. Natl Acad. Sci. USA.*, 97, 4411–4413.
126. Spector,L.G., Xie,Y., Robison,L.L., Heerema,N.A., Hilden,J.M., Lange,B., Felix,C.A., Davies,S.M., Slavin,J., Potter,J.D. et al. (2005) Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the Children’s oncology group. *Cancer Epidemiol. Biomarkers Prev.*, 14, 651–655.
127. Anderson,V.E. and Osheroff,N. (2001) Type II topoisomerases as targets for quinoline antibacterials: turning Dr. Jekyll into Mr. Hyde. *Curr. Pharm. Des.*, 7, 337–353.
128. Drlica,K. and Malik,M. (2003) Fluoroquinolones: action and resistance. *Curr. Top. Med. Chem.*, 3, 249–282.
129. Levine,C., Hsia,H. and Marians,K.J. (1998) DNA gyrase and Kuo,M.L., Shiah,S.G., Wang,C.J. and Chuang,S.E. (1999) DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poison. *Biochemistry*, 38, 15500–15507.
130. Cline,S.D. and Osheroff,N. (1999) Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by human top II enzymes. *J. Biol. Chem.*, 274, 29740–29743.
131. Sabourin,M. and Osheroff,N. (2000) Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. *Nucleic Acids Res.*, 28, 1947–1954.
132. Kingma,P.S. and Osheroff,N. (1997) Apurinic sites are position-specific topoisomerase II poisons. *J. Biol. Chem.*, 272, 1148–1155.
133. Kingma,P.S. and Osheroff,N. (1997) Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. *J. Biol. Chem.*, 272, 7488–7493.
134. Bandele,O.J. and Osheroff,N. (2008) The efficacy of topoisomerase II inhibitors in blocking DNA topology of target drug -like compounds. *Biochim. Biophys. Acta*, 1400, 233–255.
135.Baguley,B.C. and Austin,C.A. (1999) Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. *Cancer Causes Control*, 10, 143–147.
136. Baguley,B.C. and Austin,C.A. (1999) Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. *Cancer Causes Control*, 10, 143–147.
137. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase II inhibitors hypothesis: a report from the children's oncology group. *Cancer Epidemiol. Biomarkers Prev.*, 14, 651–655.
138. Kingma,P.S. and Osheroff,N. (1997) DNA lesions poison human topoisomerase IIa and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. *Biochemistry*, 36, 5934–5939.
139. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase II inhibitors hypothesis: a report from the children’s oncology group. *Cancer Epidemiol. Biomarkers Prev.*, 14, 651–655.
140. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase II inhibitors hypothesis: a report from the children’s oncology group. *Cancer Epidemiol. Biomarkers Prev.*, 14, 651–655.
141. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase II inhibitors hypothesis: a report from the children’s oncology group. *Cancer Epidemiol. Biomarkers Prev.*, 14, 651–655.
142. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase II inhibitors hypothesis: a report from the children’s oncology group. *Cancer Epidemiol. Biomarkers Prev.*, 14, 651–655.
143. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase II inhibitors hypothesis: a report from the children’s oncology group. *Cancer Epidemiol. Biomarkers Prev.*, 14, 651–655.